INTERPACE BIOSCIENCES, INC. Files Amendment No. 1 to Annual Report on Form 10-K

TL;DR

<b>Interpace Biosciences, Inc. has filed an amendment to its 2023 annual report, confirming its compliance with SEC filing requirements.</b>

AI Summary

INTERPACE BIOSCIENCES, INC. (IDXG) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Filing is an Amendment No. 1 to the Form 10-K for the fiscal year ended December 31, 2023. The company's principal executive offices are located at Waterview Plaza, Suite 310, 2001 Route 46, Parsippany, NJ 07054. The company's telephone number is (855) 776-6419. Interpace Biosciences, Inc. was formerly known as Interpace Diagnostics Group, Inc. until December 23, 2015. The company has filed all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days.

Why It Matters

For investors and stakeholders tracking INTERPACE BIOSCIENCES, INC., this filing contains several important signals. This amendment indicates that the company is actively managing its reporting obligations, which is crucial for maintaining investor confidence and regulatory compliance. The confirmation of filing all required reports suggests a period of operational stability and adherence to financial disclosure standards.

Risk Assessment

Risk Level: low — INTERPACE BIOSCIENCES, INC. shows low risk based on this filing. The filing is an amendment to a 10-K, which is a standard annual report, and does not contain new financial performance data or significant operational changes that would alter the risk profile.

Analyst Insight

Monitor future filings for updated financial performance and strategic disclosures from Interpace Biosciences, Inc.

Key Numbers

• 2023-12-31 — Fiscal Year End (Fiscal year ended December 31, 2023)
• 2024-04-26 — Filing Date (Filed as of date)
• 000-24249 — Commission File Number (SEC Commission file number)

Key Players & Entities

• INTERPACE BIOSCIENCES, INC. (company) — Registrant name
• 000-24249 (other) — Commission file number
• 20231231 (date) — Fiscal year end
• 20240426 (date) — Filing date
• Waterview Plaza, Suite 310, 2001 Route 46, Parsippany, NJ 07054 (location) — Business address
• (855) 776-6419 (phone) — Business phone number
• Interpace Diagnostics Group, Inc. (company) — Former company name
• 20151223 (date) — Date of name change

FAQ

Industry Context

The filing pertains to a company in the biotechnology or medical device sector, indicated by its former name 'Interpace Diagnostics Group, Inc.' and SIC code 3841 (Surgical & Medical Instruments & Apparatus).

Regulatory Implications

The filing is a Form 10-K/A, an amendment to an annual report, which is a standard regulatory requirement for public companies under the Securities Exchange Act of 1934.

What Investors Should Do

1. Review the full 10-K/A filing for any substantive changes or new disclosures.
2. Track future SEC filings from Interpace Biosciences, Inc. for ongoing operational and financial updates.
3. Verify the company's compliance status with relevant regulatory bodies.

Year-Over-Year Comparison

This filing is an amendment to the previous 10-K filing for the fiscal year ended December 31, 2023, indicating updates or corrections rather than a new period's performance.

Key Financial Figures

• $0.01 — Section 12(g) of the Act: Common Stock, $0.01 par value per share Indicate by check

Filing Documents

• form10-ka.htm (10-K/A) — 326KB
• ex31-3.htm (EX-31.3) — 6KB
• ex31-4.htm (EX-31.4) — 6KB
• 0001493152-24-016593.txt (&nbsp;) — 593KB
• idxg-20231231.xsd (EX-101.SCH) — 3KB
• idxg-20231231_lab.xml (EX-101.LAB) — 36KB
• idxg-20231231_pre.xml (EX-101.PRE) — 24KB
• form10-ka_htm.xml (XML) — 7KB

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 4

EXECUTIVE COMPENSATION

ITEM 11. EXECUTIVE COMPENSATION 9

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 14

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 16

PRINCIPAL ACCOUNTING FEES AND SERVICES

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES 17 PART IV 18

EXHIBITS, FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES 18 3 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Board of Directors The Board of Directors (the "Board") currently consists of five members, divided into three classes with two directors in Class I, one director in Class II and two directors in Class III. Directors serve for three-year terms with one class of directors being elected by the Company's stockholders at each annual meeting. The terms of our Class I directors, Messrs. Aggarwal and Sullivan, will expire at the 2025 annual meeting, and the term of our Class III directors, Messrs. Burnell and Keegan, will expire at the 2026 Annual Meeting. The terms of our Class II director, Mr. Rocca, will expire at the 2024 annual meeting. NAME CLASS AGE PRINCIPAL OCCUPATION OR EMPLOYMENT Vijay Aggarwal I 75 CEO of Phase Forward Technologies Thomas W. Burnell III 62 President, Chief Executive Officer and Chairman of the Board of Interpace Biosciences, Inc. Joseph Keegan, Ph.D. III 70 Independent Investor Fortunato Ron Rocca II 62 President and Chief Executive Officer of Mindera Health Stephen J. Sullivan I 77 Founder, CRO Advisors LLC The biographies and qualifications of the members of the Board are set forth below. No director is related to any of our other directors, executive officers, or persons nominated or chosen by the Company to become a director or executive officer that would require disclosure pursuant to Item 401(d) of Regulation S-K. Likewise, there are no family relationships between any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer that would require disclosure pursuant to Item 401(d) of Regulation S-K. Vijay Aggarwal, Class I Director and Ampersand Designee . Dr. Vijay Aggarwal was designated as a director by Ampersand 2018 Limited Partnership, a fund managed by Ampersand Capital Partners (" Ampers

View Full Filing

View this 10-K/A filing on SEC EDGAR